Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Mar;79(7-8):1104–1110. doi: 10.1038/sj.bjc.6690176

Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells

A Nehmé 1, R Baskaran 2, S Nebel 1, D Fink 1, S B Howell 1, J Y J Wang 2, R D Christen 1
PMCID: PMC2362240  PMID: 10098743

Abstract

Loss of DNA mismatch repair has been observed in a variety of human cancers. Recent studies have shown that loss of DNA mismatch repair results in resistance to cisplatin but not oxaliplatin, suggesting that the mismatch repair proteins serve as a detector for cisplatin but not oxaliplatin adducts. To identify the signal transduction pathways with which the detector communicates, we investigated the effect of loss of DNA mismatch repair on activation of known damage-responsive pathways, and recently reported that cisplatin differentially activates c-Jun NH2-terminal kinase (JNK) and c-Abl in repair-proficient vs.-deficient cells. In the current study, we directly compared differential activation of these pathways by cisplatin vs. oxaliplatin. The results confirm that cisplatin activates JNK kinase 5.7 ± 1.5 (s.d.)-fold more efficiently in DNA mismatch repair-proficient than repair-deficient cells, and that the c-Abl response to cisplatin is completely absent in DNA mismatch repair-deficient cells. In contrast, there was no detectable activation of the JNK or c-Abl kinases in DNA mismatch repair-proficient or -deficient cells exposed to oxaliplatin. The present study demonstrates that, despite the similarity of the adducts produced by cisplatin and oxaliplatin, they appear to be recognized by different detectors. The DNA mismatch repair system plays an important part in the recognition of cisplatin adducts, and activation of both the JNK and c-Abl kinases in response to cisplatin damage is dependent on the detector function of the DNA mismatch repair proteins. In contrast, this detector does not respond to oxaliplatin adducts. © 1999 Cancer Research Campaign

Keywords: cisplatin, oxaliplatin, JNK/SAPK, c-Abl, DNA mismatch repair

Full Text

The Full Text of this article is available as a PDF (167.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aebi S., Fink D., Gordon R., Kim H. K., Zheng H., Fink J. L., Howell S. B. Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells. Clin Cancer Res. 1997 Oct;3(10):1763–1767. [PubMed] [Google Scholar]
  2. Aebi S., Kurdi-Haidar B., Gordon R., Cenni B., Zheng H., Fink D., Christen R. D., Boland C. R., Koi M., Fishel R. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res. 1996 Jul 1;56(13):3087–3090. [PubMed] [Google Scholar]
  3. Baskaran R., Chiang G. G., Wang J. Y. Identification of a binding site in c-Ab1 tyrosine kinase for the C-terminal repeated domain of RNA polymerase II. Mol Cell Biol. 1996 Jul;16(7):3361–3369. doi: 10.1128/mcb.16.7.3361. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Baskaran R., Wood L. D., Whitaker L. L., Canman C. E., Morgan S. E., Xu Y., Barlow C., Baltimore D., Wynshaw-Boris A., Kastan M. B. Ataxia telangiectasia mutant protein activates c-Abl tyrosine kinase in response to ionizing radiation. Nature. 1997 May 29;387(6632):516–519. doi: 10.1038/387516a0. [DOI] [PubMed] [Google Scholar]
  5. Cavigelli M., Dolfi F., Claret F. X., Karin M. Induction of c-fos expression through JNK-mediated TCF/Elk-1 phosphorylation. EMBO J. 1995 Dec 1;14(23):5957–5964. doi: 10.1002/j.1460-2075.1995.tb00284.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Chen Z., Naito M., Mashima T., Tsuruo T. Activation of actin-cleavable interleukin 1beta-converting enzyme (ICE) family protease CPP-32 during chemotherapeutic agent-induced apoptosis in ovarian carcinoma cells. Cancer Res. 1996 Nov 15;56(22):5224–5229. [PubMed] [Google Scholar]
  7. Christian M. C. The current status of new platinum analogs. Semin Oncol. 1992 Dec;19(6):720–733. [PubMed] [Google Scholar]
  8. Duckett D. R., Drummond J. T., Murchie A. I., Reardon J. T., Sancar A., Lilley D. M., Modrich P. Human MutSalpha recognizes damaged DNA base pairs containing O6-methylguanine, O4-methylthymine, or the cisplatin-d(GpG) adduct. Proc Natl Acad Sci U S A. 1996 Jun 25;93(13):6443–6447. doi: 10.1073/pnas.93.13.6443. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Dérijard B., Hibi M., Wu I. H., Barrett T., Su B., Deng T., Karin M., Davis R. J. JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell. 1994 Mar 25;76(6):1025–1037. doi: 10.1016/0092-8674(94)90380-8. [DOI] [PubMed] [Google Scholar]
  10. Dérijard B., Raingeaud J., Barrett T., Wu I. H., Han J., Ulevitch R. J., Davis R. J. Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms. Science. 1995 Feb 3;267(5198):682–685. doi: 10.1126/science.7839144. [DOI] [PubMed] [Google Scholar]
  11. Eastman A. Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cells. 1990 Aug-Sep;2(8-9):275–280. [PubMed] [Google Scholar]
  12. Fink D., Zheng H., Nebel S., Norris P. S., Aebi S., Lin T. P., Nehmé A., Christen R. D., Haas M., MacLeod C. L. In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res. 1997 May 15;57(10):1841–1845. [PubMed] [Google Scholar]
  13. Fishel R., Wilson T. MutS homologs in mammalian cells. Curr Opin Genet Dev. 1997 Feb;7(1):105–113. doi: 10.1016/s0959-437x(97)80117-7. [DOI] [PubMed] [Google Scholar]
  14. Gupta S., Campbell D., Dérijard B., Davis R. J. Transcription factor ATF2 regulation by the JNK signal transduction pathway. Science. 1995 Jan 20;267(5196):389–393. doi: 10.1126/science.7824938. [DOI] [PubMed] [Google Scholar]
  15. Hawn M. T., Umar A., Carethers J. M., Marra G., Kunkel T. A., Boland C. R., Koi M. Evidence for a connection between the mismatch repair system and the G2 cell cycle checkpoint. Cancer Res. 1995 Sep 1;55(17):3721–3725. [PubMed] [Google Scholar]
  16. Hibi M., Lin A., Smeal T., Minden A., Karin M. Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain. Genes Dev. 1993 Nov;7(11):2135–2148. doi: 10.1101/gad.7.11.2135. [DOI] [PubMed] [Google Scholar]
  17. Kat A., Thilly W. G., Fang W. H., Longley M. J., Li G. M., Modrich P. An alkylation-tolerant, mutator human cell line is deficient in strand-specific mismatch repair. Proc Natl Acad Sci U S A. 1993 Jul 15;90(14):6424–6428. doi: 10.1073/pnas.90.14.6424. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Kelland L. R. New platinum antitumor complexes. Crit Rev Oncol Hematol. 1993 Dec;15(3):191–219. doi: 10.1016/1040-8428(93)90042-3. [DOI] [PubMed] [Google Scholar]
  19. Kharbanda S., Pandey P., Jin S., Inoue S., Bharti A., Yuan Z. M., Weichselbaum R., Weaver D., Kufe D. Functional interaction between DNA-PK and c-Abl in response to DNA damage. Nature. 1997 Apr 17;386(6626):732–735. doi: 10.1038/386732a0. [DOI] [PubMed] [Google Scholar]
  20. Kharbanda S., Ren R., Pandey P., Shafman T. D., Feller S. M., Weichselbaum R. R., Kufe D. W. Activation of the c-Abl tyrosine kinase in the stress response to DNA-damaging agents. Nature. 1995 Aug 31;376(6543):785–788. doi: 10.1038/376785a0. [DOI] [PubMed] [Google Scholar]
  21. Kipreos E. T., Wang J. Y. Cell cycle-regulated binding of c-Abl tyrosine kinase to DNA. Science. 1992 Apr 17;256(5055):382–385. doi: 10.1126/science.256.5055.382. [DOI] [PubMed] [Google Scholar]
  22. Koi M., Umar A., Chauhan D. P., Cherian S. P., Carethers J. M., Kunkel T. A., Boland C. R. Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N'-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation. Cancer Res. 1994 Aug 15;54(16):4308–4312. [PubMed] [Google Scholar]
  23. Kolodner R. Biochemistry and genetics of eukaryotic mismatch repair. Genes Dev. 1996 Jun 15;10(12):1433–1442. doi: 10.1101/gad.10.12.1433. [DOI] [PubMed] [Google Scholar]
  24. Liu Z. G., Baskaran R., Lea-Chou E. T., Wood L. D., Chen Y., Karin M., Wang J. Y. Three distinct signalling responses by murine fibroblasts to genotoxic stress. Nature. 1996 Nov 21;384(6606):273–276. doi: 10.1038/384273a0. [DOI] [PubMed] [Google Scholar]
  25. Liu Z. G., Hsu H., Goeddel D. V., Karin M. Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kappaB activation prevents cell death. Cell. 1996 Nov 1;87(3):565–576. doi: 10.1016/s0092-8674(00)81375-6. [DOI] [PubMed] [Google Scholar]
  26. Los G., Mutsaers P. H., Ruevekamp M., McVie J. G. The use of oxaliplatin versus cisplatin in intraperitoneal chemotherapy in cancers restricted to the peritoneal cavity in the rat. Cancer Lett. 1990 May 30;51(2):109–117. doi: 10.1016/0304-3835(90)90045-y. [DOI] [PubMed] [Google Scholar]
  27. Mattioni T., Jackson P. K., Bchini-Hooft van Huijsduijnen O., Picard D. Cell cycle arrest by tyrosine kinase Abl involves altered early mitogenic response. Oncogene. 1995 Apr 6;10(7):1325–1333. [PubMed] [Google Scholar]
  28. Mello J. A., Acharya S., Fishel R., Essigmann J. M. The mismatch-repair protein hMSH2 binds selectively to DNA adducts of the anticancer drug cisplatin. Chem Biol. 1996 Jul;3(7):579–589. doi: 10.1016/s1074-5521(96)90149-0. [DOI] [PubMed] [Google Scholar]
  29. Monks A., Scudiero D., Skehan P., Shoemaker R., Paull K., Vistica D., Hose C., Langley J., Cronise P., Vaigro-Wolff A. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst. 1991 Jun 5;83(11):757–766. doi: 10.1093/jnci/83.11.757. [DOI] [PubMed] [Google Scholar]
  30. Nehmé A., Baskaran R., Aebi S., Fink D., Nebel S., Cenni B., Wang J. Y., Howell S. B., Christen R. D. Differential induction of c-Jun NH2-terminal kinase and c-Abl kinase in DNA mismatch repair-proficient and -deficient cells exposed to cisplatin. Cancer Res. 1997 Aug 1;57(15):3253–3257. [PubMed] [Google Scholar]
  31. Orth K., Hung J., Gazdar A., Bowcock A., Mathis J. M., Sambrook J. Genetic instability in human ovarian cancer cell lines. Proc Natl Acad Sci U S A. 1994 Sep 27;91(20):9495–9499. doi: 10.1073/pnas.91.20.9495. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Saris C. P., van de Vaart P. J., Rietbroek R. C., Blommaert F. A. In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells. Carcinogenesis. 1996 Dec;17(12):2763–2769. doi: 10.1093/carcin/17.12.2763. [DOI] [PubMed] [Google Scholar]
  33. Sawyers C. L., McLaughlin J., Goga A., Havlik M., Witte O. The nuclear tyrosine kinase c-Abl negatively regulates cell growth. Cell. 1994 Apr 8;77(1):121–131. doi: 10.1016/0092-8674(94)90240-2. [DOI] [PubMed] [Google Scholar]
  34. Schmidt W., Chaney S. G. Role of carrier ligand in platinum resistance of human carcinoma cell lines. Cancer Res. 1993 Feb 15;53(4):799–805. [PubMed] [Google Scholar]
  35. Shafman T., Khanna K. K., Kedar P., Spring K., Kozlov S., Yen T., Hobson K., Gatei M., Zhang N., Watters D. Interaction between ATM protein and c-Abl in response to DNA damage. Nature. 1997 May 29;387(6632):520–523. doi: 10.1038/387520a0. [DOI] [PubMed] [Google Scholar]
  36. Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D., Warren J. T., Bokesch H., Kenney S., Boyd M. R. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst. 1990 Jul 4;82(13):1107–1112. doi: 10.1093/jnci/82.13.1107. [DOI] [PubMed] [Google Scholar]
  37. Umar A., Koi M., Risinger J. I., Glaab W. E., Tindall K. R., Kolodner R. D., Boland C. R., Barrett J. C., Kunkel T. A. Correction of hypermutability, N-methyl-N'-nitro-N-nitrosoguanidine resistance, and defective DNA mismatch repair by introducing chromosome 2 into human tumor cells with mutations in MSH2 and MSH6. Cancer Res. 1997 Sep 15;57(18):3949–3955. [PubMed] [Google Scholar]
  38. Yuan Z. M., Huang Y., Ishiko T., Kharbanda S., Weichselbaum R., Kufe D. Regulation of DNA damage-induced apoptosis by the c-Abl tyrosine kinase. Proc Natl Acad Sci U S A. 1997 Feb 18;94(4):1437–1440. doi: 10.1073/pnas.94.4.1437. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES